Investor News

INVESTOR NEWS

2019

29. October 2019 - Preliminary IFRS result for third quarter of 2019

Preliminary IFRS result for third quarter of 2019: NAV per share at EUR 5.60 still well above current stock level

Berlin, October 29, 2019: MPH Health Care AG (ISIN: DE000A0L1H32) announces preliminary IFRS results for the third quarter of 2019. The equity of the investment company amounted to EUR 239.57 million as of September 30, 2019 (previous year: EUR 281.00 million). The net asset value (NAV) per share was Euro 5.60 (previous year: Euro 6.56) and thus still well above the current price level (Xetra closing price 28 October 2019: Euro 3,72).

The decline in the share price of HAEMATO AG from EUR 4.65 per share (31.12.2018) to EUR 3.01 per share on 30.09.2019 in particular led to a decline in the NAV. HAEMATO AG has taken extensive measures to increase earnings (e.g. streamlining the product portfolio) and is currently in the process of establishing new personnel and digital structures in the product management, procurement and sales divisions.

“We are confident about the further development of our listed investments HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG despite the short-term decline in the share price. M1 and CR in particular are developing very positively in operational terms and HAEMATO is currently implementing important measures to increase earnings,” says Patrick Brenske, member of the Management Board of MPH.

read more

29. August 2019 - Interim Report 2019

1st half-year 2019 of MPH Health Care AG: Investment companies develop according to plan and net asset value (NAV) of EUR 5.86 significantly above current share price

Berlin, 29. August 2019. The net asset value (NAV) of MPH Health Care AG (ISIN: DE000A0L1H32) was EUR 5.86 per share at the end of the first half of 2019, well above the current share price (Xetra closing price 28 August: EUR 3.89). Due to the continuing good results of the investments, MPH again distributed a dividend of 20 cents per share in July 2019. This corresponds to a dividend yield of 5,1%.

MPH’s listed and significant equity investments developed according to plan in the first half of 2019:

CR Capital Real Estate AG has increased its dividend for the 2018 financial year by 50% to EUR 1.50 per share and also resolved to issue new no-par value shares (bonus shares) at a ratio of 1:1. In the first six months of the current year, the company continued its positive business development. Sales amounted to EUR 6.32 million (H1/2018: EUR 12.83 million). The real estate company significantly increased its net income for the first half of the year from EUR 2.10 million to EUR 3.47 million. Currently, two projects are in the construction phase and others are in concrete development. For 2019 as a whole, the company expects earnings growth of around 30 percent. In addition to its positive operating performance, CR Capital Real Estate has expanded its business model in recent months. In the future, social housing will be another focus area. Thanks to its proven price-conscious design, CR is well placed to enter the social housing segment and create added value for both tenants and shareholders.

At its Annual General Meeting, M1 Kliniken AG approved the distribution of a dividend for 2018 of EUR 0.30 per share. Demand for the medical aesthetic services of the M1 Group continued to develop positively in the first half of 2019. Group sales rose from EUR 28.9 million to EUR 32.9 million. Germany’s market leader in the field of beauty medicine is profiting more and more from the investments made in recent years. The growth driver in the first half of the year was the strong-margin core segment “Beauty”, whose sales increased by more than 40 percent to EUR 20.3 million. Earnings before taxes (EBT) rose in the reporting period by 21 percent to EUR 5.2 million. In addition to the positive operating development, the M1 Group also set the course for further growth in Germany and abroad in the reporting period. Four further specialist centres were opened until end of July. In addition, treatment capacities were expanded at several German locations. The M1 Group has already established cosmetic laser treatments in ten beauty centres and is successfully exploiting cross-selling potential. By the end of the year, the services of “M1 Laser” are to be offered in almost all German locations. Based on this positive business development, M1 Kliniken has confirmed its operating targets for 2019: Double-digit increase in Group sales and earnings. In the second half of 2019, numerous new locations in Germany and abroad will be added and will contribute to the Group’s operational growth in the future.

HAEMATO AG has approved a dividend of EUR 0.10 per share for 2018. The product portfolio is currently being realigned and internal processes optimized and digitized. The pharmaceutical company, which focuses on the growth markets of high-priced special pharmaceuticals, is currently establishing new personnel and digital structures in product management, procurement and sales in order to exploit the existing market potential more extensively in the future. As expected, the company’s operating performance in the first half of the year was significantly below the previous year’s level. HAEMATO achieved sales of EUR 94.0 million and earnings before interest and taxes (EBIT) of EUR 0.7 million. After HAEMATO adjusted its product portfolio for low-margin products last year, capacities are now available for the introduction of new products. This includes the trading of narcotics (including medical cannabis) and the development of medical products. This means broadening the product range in segments with above-average growth.

The Half Year Report 2019 of MPH Health Care AG for download: www.mph-ag.de/investor-relations

read more

18. July 2019 - HV 2019

MPH Health Care AG successfully holds Annual General Meeting – Dividend distribution of EUR 0.20 per share resolved

Berlin, July 18th, 2019: MPH Health Care AG (“MPH”) successfully held the Annual General Meeting 2019 yesterday. The resolution on all items on the agenda of this year’s Annual General Meeting was passed with a majority of more than 99%.

A total of 56% of the share capital was represented at the Annual General Meeting. The items on the agenda included the resolution on the appropriation of the 2018 balance sheet profit, the ratification of the actions of the members of the Management Board and Supervisory Board and the election of the auditor for the 2019 financial year.

The shareholders followed the proposal of the Management Board and Supervisory Board to distribute a dividend of EUR 0.20 per share for the 2018 financial year with a large majority. All other resolutions were also approved by a large majority. The detailed voting results were published at: https:// www.mph-ag.de/investor-relations/.

The dividend is due on Monday, 22 July 2019.

About MPH Health Care AG:About MPH Health Care AG:MPH AG is an investment company with a strategic focus on the acquisition, development and sale of companies and company shares, particularly in growth segments of the healthcare market. This includes both insurance-financed and privately financed segments. However, MPH also exploits the potential of high-growth and high-yield sectors outside the healthcare market.

MPH Health Care AG shares are listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange.

Key figures for the MPH Health Care AG shares:

Subscribed capital: EUR 42,813,842
Listed class of shares: Bearer ordinary shares
ISIN: DE000A0L1H32
Security identification number: A0L1H3
stock exchange code: 93M

read more

23. May 2019 - Q1 Results 2019

Corporate News of MPH Health Care AG: Q1 Results

First Quarter 2019: Preliminary IFRS-result, equity (Net Asset Value) of 263.49 million EUR and therefore 6.15 EUR per share.

Berlin, 23rd May, 2019: MPH Health Care AG (ISIN: DE000A0L1H32) announces preliminary IFRS results for the first quarter of 2019. Accordingly, the preliminary IFRS period loss amounted to -5.64 million EUR (previous year: period profit of 26.75 million EUR). The reason for the net loss for the period lies in the fair value measurement of the share prices of the investments on 31 March 2019 compared to the share prices on 31 December 2018.

Equity amounted to 263.49 million EUR as of 31 March 2019 (previous year: 267.42 million EUR). Net asset value (NAV) fell slightly year-over-year from 6.25 EUR (31 March 18) to 6.15 EUR (31 March 19) per share.

“We are confident about the further development of our listed investments HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG in 2019, despite the brief decline in the share price. The healthcare market in Germany has been growing faster than the economy as a whole for many years now, and we are systematically benefiting from this with our investments, e.g. with HAEMATO for pharmaceuticals in the insurance-financed market and with M1 Kliniken in the private payer market,” says Patrick Brenske, CEO of MPH.

Due to the sustained positive results of recent years, the Executive Board will propose an unchanged dividend of 20 cents per share at the Annual General Meeting on 17 July 2019.

The Annual Report 2018 of MPH Health Care AG was published on the website on May 22, 2019 and is available for download at https://www.mph-ag.de/en/en/reports/. Net asset value increased by 12% from 5.62 EUR (31 Dec. 17) to 6.29 EUR (31 Dec. 18) per share in the fiscal year 2018.

read more

11. April 2019 - Preliminary IFRS result 2018

MPH Health Care AG: Preliminary IFRS result 2018

2018: Net income 37.03 million euro, earnings per share 0.87 euro (previous year 31.86 million euro, earnings per share 0.74 euro). The net asset value was euro 6.29 per share (previous year euro 5.62).

Berlin, April 11, 2019: Preliminary IFRS result: MPH Health Care AG, Berlin (ISIN: DE000A0L1H32), announces preliminary IFRS consolidated result for fiscal year 2018. In the 2018 financial year, the preliminary IFRS net income amounted to 37.03 million euro (0.87 euro earnings per share).

HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG, which are listed on the Frankfurt Stock Exchange, continued to operate successfully in the 2018 financial year.

HAEMATO AG was able to achieve consolidated sales of 274.1 million euro, an EBITDA of 10.0 million euro and a net profit of 6.3 million euro (according to IFRS 15). The improvement in operating gross profit was just under 1 %. Financial liabilities were reduced significantly by a total of euro 10.9 million, based on the cancellation of the profit participation certificates. The Management Board has announced that the Supervisory Board will propose an unchanged dividend of 30 cents per share for the 2018 financial year.

M1 Kliniken AG was able to increase the number of treatments performed in the past financial year to almost 190,000, further extending its market leadership. A key element here is the further increase in the number of M1 specialist centres from 17 (as 31.12.2017) to 24 (as 31.12.2018). The international expansion was initiated with the first M1 specialist centre in Vienna. In 2018, the product range was expanded to include aesthetic dental and laser treatments with M1 Dental and M1 Laser. The continuation of the expansion to a total of 50 specialist centres is planned for 2020.

The M1 share price rose from euro 13.20 on January 2, 2018 to euro 15.00 on December 31, 2018. In September 2018, the share capital was increased by € 1,000,000.00 to euro 17,500,000.00 by means of a capital increase through the issue of a total of 1,000,000 bearer shares. The dividend paid in June 2018 amounted to 30 cents per share.

CR Capital Real Estate AG was again able to significantly increase its net profit for the 2018 financial year by 33% to euro 7.7 million, whitch is euro 1.9 million above the previous year’s result of euro 5.8 million. Sales increased by +123% to euro 23.2 million, earnings per share by +30% to euro 4.10 (previous year euro 3.14). The share price of CR Capital Real Estate AG increased from euro 20.80 on January 2, 2018 to euro 32.60 on December 31, 2018. Due to the extremely positive result, the Management Board proposes to increase the dividend for the 2018 financial year and to issue bonus shares, which would be fully entitled to dividends from the 2019 financial year onwards.

“We are confident about the further development in 2019. Since 2005, the healthcare industry has expanded its gross value added more strongly than the economy as a whole every year. MPH benefits systematically from the growth of HAEMATO AG with drugs in the insurance-financed market and M1 Kliniken AG in the private payer market, the so-called second health market. This is also reflected in the comparison of the share price performance with the SDAX.

In recent years, a dividend of 12 cents has been distributed, and for the 2017 financial year a dividend of 20 cents per share has been distributed. Due to the continuing positive results of recent years, we will again propose a dividend of 20 cents per share for 2018 at the Annual General Meeting,” said Patrick Brenske, CEO of MPH.

read more

2018

3. December 2018 - 2018 Developing

MPH Health Care AG: Investments developing positive

  •  CR Capital Real Estate raises sales and profit forecast
  • Haemato increases earnings by approx. 50% in the first 9 months
  • M1 Kliniken opens further locations

Berlin, 03 December 2018: The affiliated companies of MPH Health Care AG (ISIN: DE000A0L1H32) have confirmed their growth course with positive news.

CR Capital Real Estate AG has significantly increased its sales and profit forecast for the current year 2018. The real estate company focuses on the creation of affordable living space in the metropolises of Berlin and Leipzig and their environs. Group sales in 2018 are expected to increase from EUR 10.4 million in the previous year to over EUR 20 million. The annual surplus is to rise from 5.8 million euros to over 7 million euros. The project in Schkeuditz with 96 terraced houses is decisive for the positive development. In addition, plots close to Berlin were acquired. Here, too, semi-detached and terraced houses are expected to be built.

HAEMATO AG reported on the development in the first nine months of 2018. The provider of special pharmaceuticals increased its profit by 50.5 percent from EUR 3.9 million to EUR 5.87 million compared to the same period of the previous year. Sales increased slightly from EUR 211.3 million to EUR 212.8 million. HAEMATO specializes in drugs for the treatment of chronic diseases and sees further growth potential. In addition, the operating margin is to be increased sustainably. Therefor, the Executive Board is working on optimizing business processes through digitization.

M1 Kliniken AG, the number 1 in the field of beauty medicine in Germany, continues its expansion course in 2018. 4 new specialist centres have been opened so far this year. Two more are to follow by the end of the year. The M1 Group will thus operate a total of 24 specialist centres for aesthetic treatments by the end of 2018. The increase of more than 30% compared to the previous year is in line with corporate planning. M1 Kliniken AG is thus creating an important condition for a further significant increase in sales in the coming year.

read more

30. October 2018 - Q3 Results 2018

Investment company MPH Health Care AG increases net asset value by 27.6 % to EUR 6.56 per share as of 30.09.2018

  • Net income for the period of 48.90 million euros
  • Equity ratio increases to 94.2 %

Berlin, 30. Oktober 2018: MPH Health Care AG (ISIN: DE000A0L1H32) continued to benefit from the successful development of its portfolio companies in the first nine months of 2018. The net asset value (NAV) per share rose year-on-year by 27.6 % from EUR 5.14 to EUR 6.56 as of September 30, 2018. This means that the NAV is still well above the current share price (Xetra closing price on October 29, 2018: EUR 4.17).

In the first nine months of 2018, MPH generated a preliminary IFRS period surplus of EUR 48.90 million (previous year: EUR 11.22 million). This pleasing result was achieved through a corresponding increase in the value of financial investments. Compared with the end of 2017, equity rose from EUR 240.67 million to EUR 281.00 million.

“The health care and construction industries in Germany have been growing faster than the economy as a whole for years, and with our investments we benefit systematically, e.g. through the growth of HAEMATO AG with pharmaceuticals in the insurance-financed market, M1 Kliniken AG in the private payer market and CR Capital Real Estate AG in the affordable new residential constructions for owner-occupiers. We are therefore confident that this positive development will continue,” says Patrick Brenske, CEO of MPH.

read more

31. August 2018 - Interim Report 2018

Investment company MPH Health Care AG with successful first half-year of 2018: Net asset value rises by 43 % to EUR 6.93 per share

  • Net earnings EUR 55.9 million (previous year: EUR -2.2 million)
  • Investments: HAEMATO has more than doubled its EBIT; M1 Kliniken grows by 30 %; CR Capital benefits from great interest in the “Halle Gardens” construction project in Schkeuditz/Leipzig
  • Dividend payment of 20 cents per share (previous year: 12 cents) made in July

Berlin, 31 August 2018: MPH Health Care AG (ISIN: DE000A0L1H32) benefited from the successful development of its portfolio companies in the first half-year of 2018. The net asset value (NAV) per share rose year-on-year by 43.4 % from EUR 4.83 to EUR 6.93. With this, the NAV continues to exceed the current share price considerably (Xetra closing on August 30: EUR 4.54).

IFRS equity capital amounted to EUR 296.6 million at the reporting date of 30 June 2018 (H1 2017: EUR 206.6 million). MPH increased its net earnings (IFRS) in the first half-year of 2018 to EUR 55.9 million (H1 2017: EUR -2.2 million).

“Our listed investments in HAEMATO, M1 Kliniken and CR Capital Real Estate have continued their successful development in the first half-year of 2018,” says Patrick Brenske, CEO of MPH. “With our focus on growth companies of the German health care market, we systematically benefit from the industry’s above-average development compared to the overall economy. We were therefore able to pay a significantly higher dividend of 20 cents per share in July 2018.”

The three major portfolio companies of MPH Health Care AG recorded a positive development in the first half-year of 2018.

HAEMATO AG, a pharmaceutical company focusing on the growth markets of high-priced specialty pharmaceuticals, more than doubled its earnings before interest and taxes (EBIT) – with slightly increasing sales – to EUR 6.5 million compared to the previous year in the first half-year of 2018.

M1 Kliniken AG, a leading private provider of health services in the field of aesthetic medicine in Germany, continued its profitable growth course and increased Group sales by 30% to EUR 28.9 million. For the second half-year of 2018, not only additional M1 Med Beauty locations, but also further specialist centres for aesthetic dental treatments under the new brand “M1 Dental” are planned. In addition, M1 is targeting its internationalisation. The first international location is to be opened in Vienna in the second half of 2018.

CR Capital Real Estate AG, which focuses on project developments in the residential and health care real estate sectors, has successfully continued its current construction project “Halle Gardens” in Schkeuditz/Leipzig. The first residential units were handed over to the new owners in April. The complete handover of the first construction phase with 96 residential units is to take place until autumn 2018. Due to the high demand, CR has already acquired further adjacent areas and is planning further new buildings there. In addition, CR has secured plots in the Berlin surroundings, in attractive quality locations with good infrastructure.

 The Half Year Report 2018 of MPH Health Care will be available for download from www.mph-ag.de/investor-relations later today.

 

read more

13. July 2018 - hv_2018

Significant dividend increase from 0.12 EUR to 0.20 EUR per share approved

  • Dividend yield at 4 %
  • Annual general meeting approves all agenda items

Berlin, May 11, 2018: MPH Health Care AG (ISIN: DE000A0L1H32) will continue to benefit from the successful development of its associated companies in the current year. At MPH, this is reflected in the increase in the value of financial investments. In the first quarter of 2018, the associated company generated preliminary net income (IFRS) of EUR 26.75 million (previous year: EUR -2.39 million). Equity rose to EUR 267.42 million (previous year: EUR 211.56 million). Net asset value (NAV) rose year-on-year from EUR 4.94 to EUR 6.25 per share, well above the current share price.

“Our listed investments HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG have made a successful start to 2018,” says Patrick Brenske, CEO of MPH. “The healthcare market in Germany has been growing faster than the economy as a whole for years and we are systematically benefiting from this through our investments. With HAEMATO for drugs in the insurance-financed market and with M1 clinics in the private payer market. We are therefore confident that this positive development will continue.”

Due to the sustained positive results of recent years, the Executive Board will propose to the annual general meeting on July 11, 2018 a dividend increase from 12 cents per share to 20 cents per share for the financial year 2017.

The Annual Report 2017 of MPH Health Care AG is available for download at www.mph-ag.de//en/investor-relations

read more

11. May 2018 - Q1 Results 2018

Net asset value rises in Q1/2018 to EUR 6.25 per share and dividend for 2017 to be significantly increased

  • All investments develop positively
  • Dividend increase for 2017 from 12 cents to 20 cents per share

Berlin, May 11, 2018: MPH Health Care AG (ISIN: DE000A0L1H32) will continue to benefit from the successful development of its associated companies in the current year. At MPH, this is reflected in the increase in the value of financial investments. In the first quarter of 2018, the associated company generated preliminary net income (IFRS) of EUR 26.75 million (previous year: EUR -2.39 million). Equity rose to EUR 267.42 million (previous year: EUR 211.56 million). Net asset value (NAV) rose year-on-year from EUR 4.94 to EUR 6.25 per share, well above the current share price.

“Our listed investments HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG have made a successful start to 2018,” says Patrick Brenske, CEO of MPH. “The healthcare market in Germany has been growing faster than the economy as a whole for years and we are systematically benefiting from this through our investments. With HAEMATO for drugs in the insurance-financed market and with M1 clinics in the private payer market. We are therefore confident that this positive development will continue.”

Due to the sustained positive results of recent years, the Executive Board will propose to the Annual General Meeting on July 11, 2018 a dividend increase from 12 cents per share to 20 cents per share for the financial year 2017.

The Annual Report 2017 of MPH Health Care AG is available for download at www.mph-ag.de/investor-relations

read more

29. March 2018 - Ad hoc – Preliminary IFRS result 2017

Ad hoc of MPH Health Care AG: Preliminary IFRS result 2017

2017: Preliminary IFRS result, net income 31.86 million euros, earnings per share 0.74 euros (previous year: 80.07 million euros, earnings per share 1.87 euros). Equity EUR 240.67 million (previous year: EUR 213.95 million). Net Asset Value per share of EUR 5.62.

MPH Health Care AG, Berlin (ISIN: DE000A0L1H32), announces its preliminary consolidated IFRS results for the financial year 2017. The preliminary IFRS net income amounted to EUR 31.86 million (EUR 0.74 earnings per share).

HAEMATO AG, which is listed on the Frankfurt Stock Exchange, M1 Kliniken AG and CR Capital Real Estate AG continued to operate successfully in the financial year 2017.

HAEMATO AG was able to increase the consolidated IFRS sales by 5 % to 289.9 million Euro and thereby achieve an EBIT of 9.4 million Euro and a net income of 7.0 million Euro. As in previous years, the dividend paid in June 2017 was 30 cents per share.

M1 Kliniken AG was able to significantly increase its consolidated sales by 31 % to Euro 47.2 million and EBT by 36 % to Euro 7.4 million. In particular, this was due to the opening of six new medical centers in 2017, bringing the total number of M1 centers serving customers nationwide as of December 31, 2017 to 17. The M1 share price rose from EUR 10.80 to EUR 13.18 during the year. The dividend paid in June 2017 was 30 cents per share.

CR Capital Real Estate AG more than doubled its net income to EUR 4.7 million in fiscal year 2017 (previous year: EUR 2.2 million). The consolidated IFRS sales fell to ca. EUR 10.0 million (previous year: EUR 17.5 million). As a result of an ordinary capital reduction pursuant to §§ 222 ff. the stock price of CR Capital Real Estate AG increased from (converted) EUR 19.00 to EUR 20.31 during the year. Due to the extremely positive result, a dividend of EUR 1.00 per share (previous year no dividend) is planned for fiscal 2017.

“We are confident about the further development in 2018. Since 2005, every year the healthcare industry has expanded its gross value added more strongly than the economy as a whole. MPH benefits systematically from this through the growth of HAEMATO AG with drugs in the insurance-financed health care market and M1 Kliniken AG in the private payer market, the so-called second health care market.

“In recent years, a dividend of 12 cents per share has been paid. Based on the positive results of the last three years, we will propose a dividend of 20 cents per share for 2017 to the Annual General Meeting,” says Patrick Brenske, MPH Board Member.

read more

2017

30. October 2017 - Q3 Results 2017

Preliminary IFRS results in the first nine month of 2017

Berlin, 30. October 2017 – MPH Health Care AG: Growth in the third quarter of 2017

  • Value of portfolio holdings increases by 6,68% to EUR 226,67 million
  • Equity ratio increases to 93%
  • Positive development in the healthcare market

In the first nine months of 2017, MPH achieved a preliminary IFRS net income of EUR 11.22 million. Equity increased from EUR 213.95 million in the previous year to EUR 220.03 million.

The share price of MPH rose by 13.2% to EUR 3.43 compared to the third quarter of 2016. The net asset value per share increased to EUR 5.14. The increase in value of MPH’s portfolio holdings resulted in net income for the third quarter of EUR 13.42 million.

MPH’s portfolio companies HAEMATO AG (pharma) and M1 Kliniken AG (clinics) are benefiting from the continued positive development within their growth segments. HAEMATO AG, a specialist in oncology, HIV and other chronic diseases, generates further growth through the high demand for personalized medicine. The market volume is around EUR 10 billion and is growing at an annual rate of 10%.

Kliniken AG benefits from the rapidly growing beauty market. With now more than 50 doctors and 15 locations in Germany, M1 is the leading chain of clinics in major segments of beauty medicine. The growth amounts to approx. 20% -30% p.a.. The company’s aim is to open up further locations also internationally and at the same time to steadily expand the treatment offer in the outpatient area.

The real estate developer CR Capital Real Estate AG increased their sales quota to more than 50% for the first construction phase of the property in Schkeuditz at Leipzig.

read more

31. August 2017 - Interim Report 2017

Interim Report 2017

Berlin, 31 August 2017 – MPH Health Care AG strengthened its activities in the health care market; Net asset value (NAV) per share and share price significantly increased compared to the previous year’s period

• Increase in the net asset value of the share by 35% to EUR 4.83

• Share price rose by 46% to EUR 3.66 (compared to 30 June 2016). Valuation gap partially closed.

This year’s Annual General Meeting decided to rename MPH into “MPH Health Care AG”. This intends to make it even clearer that MPH acts as an investment company aiming at the development of entrepreneurial opportunities in the health care market. As in the previous year a dividend payment of € 0.12 / share was decided.

In the first half of 2017, MPH Health-Care AG successfully continued its growth path. Our company and our holdings were able to record a very gratifying development overall. MPH’s net asset value per share rose by 35% from EUR 3.58 to EUR 4.83 compared to the previous year’s period. At the end of the first half-year of 2017, the share price rose by 45.8% compared to June 30, 2016 (price on June 30, 2016: EUR 2.56 / share). This increase closed some of the remaining valuation gap to about 24%.

The company will provide the interim report for the reporting period from January 1, 2017 to June 30, 2017 as of today.

read more

7. July 2017 - Change in Management Board

First quarter 2017: Preliminary IFRS-Result, period loss – EUR 2.39 million. Equity EUR 211.56 million and thereby EUR 4.94 per share. Publication of the annual report 2016 on April, 28, 2017.

MPH Mittelständische Pharma Holding AG, Berlin (ISIN: DE000A0L1H32), announces the preliminary IFRS result for the first quarter of 2017. In the first quarter of 2017, the preliminary IFRS loss for the period was EUR -2.39 million. The reason for the loss in the period is the lower share price level of the shareholdings on March 31, 2017, compared to the share prices on December 31, 2016.

“We are positively assessing the operating performance in the first quarter of 2017 of HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG. We are confident about the further development in 2017 despite the short-term decline in the share price. It remains the case that the Management Board proposes an unchanged dividend compared to last year, which is 12 cents per share, at the Annual General Meeting, “said Patrick Brenske and Dr. Christian Pahl, MPH Board Members.

On this day MPH will publish the annual report 2016 on the website. As already provisionally announced, the annual net profit for the year of MPH amounted to EUR 80.1 million for the financial year 2016.

read more

28. April 2017 - Q1 Results 2017

First quarter 2017: Preliminary IFRS-Result, period loss – EUR 2.39 million. Equity EUR 211.56 million and thereby EUR 4.94 per share. Publication of the annual report 2016 on April, 28, 2017.

MPH Mittelständische Pharma Holding AG, Berlin (ISIN: DE000A0L1H32), announces the preliminary IFRS result for the first quarter of 2017. In the first quarter of 2017, the preliminary IFRS loss for the period was EUR -2.39 million. The reason for the loss in the period is the lower share price level of the shareholdings on March 31, 2017, compared to the share prices on December 31, 2016.

“We are positively assessing the operating performance in the first quarter of 2017 of HAEMATO AG, M1 Kliniken AG and CR Capital Real Estate AG. We are confident about the further development in 2017 despite the short-term decline in the share price. It remains the case that the Management Board proposes an unchanged dividend compared to last year, which is 12 cents per share, at the Annual General Meeting, “said Patrick Brenske and Dr. Christian Pahl, MPH Board Members.

On this day MPH will publish the annual report 2016 on the website. As already provisionally announced, the annual net profit for the year of MPH amounted to EUR 80.1 million for the financial year 2016.

read more

17. March 2017 - Preliminary IFRS-Results 2016

2016: Temporary IFRS results, annual net profit of €81.45m, €1.90 profit per share (previous year: €84.10m, €1.96 profit per share). Equity €215.33m (previous year: €139.02m).

MPH Mittelständische Pharma Holding AG, Berlin (ISIN: DE000A0L1H32), announces the temporary IFRS group results for fiscal year 2016. In fiscal year 2016, the temporary IFRS annual net profit was €81.45m (€1.90 profit per share).

“HAEMATO AG, M1 Kliniken AG, and CR Capital Real Estate AG holding companies listed in the Frankfurt Stock Exchange operated successfully in 2016.
In fiscal year 2016, HAEMATO achieved an increase in turnover of 20%, an EBIT growth of 63%, and an increase of the annual net profit of 94%.

During the fiscal year, the HAEMATO share price increased from €4.94 to €6.44. As in the previous year, the dividend paid in June 2016 was €0.30 per share.

M1 Kliniken AG expanded its clinic in Berlin to 6 operating theatres and 35 patient beds. After some more openings, 13 M1 centres of competence are now ready to serve our customers throughout Germany. The financial data for 2016 will be published on 31.03.2017.

The M1 share price has almost doubled from €5.34 to €10.55 during the fiscal year. The dividend paid in June 2016 was €0.30 per share.

CR Capital Real Estate AG reported progress in the project developments at the annual general meeting on 18.08.2016. The 2016 financial data will presumably be published in March 2017.

Following last year’s annual net profit of €84.10m, the annual net profit of €81.45m is another record result. This allows us to be confident regarding the further development in 2017. In each year since 2005, the health care industry has expanded its gross value added more strongly than the overall economy. MPH systematically benefits from the growth of HAEMATO AG in the field of pharmaceuticals in the insurance-financed market and through the growth of M1 Kliniken AG in the direct-payer market, the so-called secondary health care market.

The results situation allows us to propose at the annual general meeting a dividend of €0.12 per share, which is the same amount as last year”, note both Patrick Brenske and Dr Christian Pahl, Members of the Board of MPH.

read more